Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H M Jolson

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Pacing and Clinical Electrophysiology : PACE|April 1, 1992
Propafenone associated agranulocytosisL J Miwa, H M Jolson
JAMA|May 13, 1992
TB or not TB, that is the questionH M Jolson, R E Behrman
Archives of Internal Medicine|May 11, 1991
Adverse reaction reporting of interaction between warfarin and fluoroquinolonesH M Jolson, L A Tanner, L Green, et al.
The Annals of Pharmacotherapy|July 1, 1994
Alternatives to intravenous tetracycline hydrochloride for malignant pleural effusionsT H Grasela, C A Walawander, H M Jolson, et al.
American Journal of Hospital Pharmacy|September 1, 1993
Capability of hospital computer systems in performing drug-use evaluations and adverse drug event monitoringT H Grasela, C A Walawander, D L Kennedy, et al.
Journal of Clinical Epidemiology|July 1, 1996
The incidence of depression in new users of beta-blockers and selected antihypertensivesB B Gerstman, H M Jolson, M Bauer, et al.
Journal of the National Cancer Institute|April 1, 1992
Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabineH M Jolson, L Bosco, M G Bufton, et al.
Antiviral Therapy|March 21, 2000
Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study GroupL E Chapman, G J Mertz, C J Peters, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2002
Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndromeL E Chapman, B A Ellis, F T Koster, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Pacing and Clinical Electrophysiology : PACE|April 1, 1992
Propafenone associated agranulocytosisL J Miwa, H M Jolson
JAMA|May 13, 1992
TB or not TB, that is the questionH M Jolson, R E Behrman
Archives of Internal Medicine|May 11, 1991
Adverse reaction reporting of interaction between warfarin and fluoroquinolonesH M Jolson, L A Tanner, L Green, et al.
The Annals of Pharmacotherapy|July 1, 1994
Alternatives to intravenous tetracycline hydrochloride for malignant pleural effusionsT H Grasela, C A Walawander, H M Jolson, et al.
American Journal of Hospital Pharmacy|September 1, 1993
Capability of hospital computer systems in performing drug-use evaluations and adverse drug event monitoringT H Grasela, C A Walawander, D L Kennedy, et al.
Journal of Clinical Epidemiology|July 1, 1996
The incidence of depression in new users of beta-blockers and selected antihypertensivesB B Gerstman, H M Jolson, M Bauer, et al.
Journal of the National Cancer Institute|April 1, 1992
Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabineH M Jolson, L Bosco, M G Bufton, et al.
Antiviral Therapy|March 21, 2000
Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study GroupL E Chapman, G J Mertz, C J Peters, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2002
Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndromeL E Chapman, B A Ellis, F T Koster, et al.
Pageof 1